Anumigilimab

CAS No. 2416593-08-1

Anumigilimab( —— )

Catalog No. M36769 CAS No. 2416593-08-1

Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 375 Get Quote
5MG 586 Get Quote
10MG 834 Get Quote
25MG 1224 Get Quote
50MG 1647 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Anumigilimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.
  • Description
    Anumigilimab (CSL-324) is an humanized IgG2a mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    CSF1R
  • Recptor
    c-Fms
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2416593-08-1
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Markota ?agalj A, et al. New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int J Mol Sci. 2022 Mar 29;23(7):3753. ?
molnova catalog
related products
  • Axatilimab

    Axatilimab (SNDX-6352) is a human IgG4 antibody targeting the colony-stimulating factor 1 receptor (CSF-1R), which can be used for the study of immune system disorders and respiratory diseases.

  • Gimsilumab

    Gimsilumab (MORAb-022) is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor for the study of COVID-19-induced inflammation and hypoxemia.

  • Mavrilimumab

    Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that targets the α subunit of the granulocytic-macrophage colony-stimulating factor (GM-CSF) receptor, inhibiting downstream intracellular GM-CSF signaling.